Chinese Pharmaceutical Market Size and Research Report 2024: Radiant Insights, Inc From 2008 to 2013, China’s OTC drugs market reported an average growth of 15% with the market reaching $20.6bn in 2013 up from to $11bn in 2008 - but what will it be this year? Next year? and in 5 years time? The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access – and this is only the OTC market – what has the growth been throughout the whole Chinese pharma sector? This report will tell you. China’s pharmaceutical sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market? View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world’s diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types – your company must capture a segment of this market TODAY. Anti-Counterfeiting and anti-corruption – How the Chinese market is changing Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.
Increased inward investment from multiple ‘Big Pharma’ companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel. Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market. Increase in healthcare expenditure per capita, from $157in 2008 to $278 in 2011 Increasing income and population. The middle class population reached 400m in 2010 and is expected to reach 500m by 2015 View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market In 2012, the central government alone invested CNY 24.3bn ($3.9bn) to improve health service infrastructure. Key life style changes, which have accelerated the diseases such as obesity, diabetes, cardiovascular, chronic respiratory diseases The over 65 population has increased to 9.1% of the total population in China in 2011 from 8.3% in 2008 This report also breaks down the market in terms of current drugs and products that occupy the Chinese market at present; examining the key prescription and OTC drugs that drive the Chinese market. In addition to this crucial information this report offers analysis and opinion on current R&D in the country alongside in depth analysis of the evolving, global inward investment. Discover exactly what the industry leaders are doing TODAY Industry information sourced exclusively for this report. This information is not available anywhere else Utilising primary and secondary research sources, GMR Data have interviewed leading specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations specialising in access to the Chinese market, as well as Chinese pharmaceutical companies accessing the global market. From these interviews we have
selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else. This GMR Data report is the single tool to equip you with the latest trends in all pharma sectors and why all stakeholders demand development of the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market. With over 160 pages, and over 140+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market. View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market Table of Contents 1. Executive Summary 1.1. Chinese Pharmaceutical Market Review 1.2. Chapter Breakdown 1.3. Research and Analysis Methods 2. Drivers & Restraints of the Chinese Pharmaceutical Market 2.1 An Ageing Population will drive pharmaceutical market growth in China 2.2 Increase in Chinese urbanisation 2.3 Increase in Healthcare expenditure will increase drug demand in China 2.4 Government policies and changing environment for MNCs in China 2.5 Increased demand for improved drug quality 2.6 Healthcare Reform in China
2.7 Path to privatization of Chinese healthcare 2.8 Consolidation of the pharmaceutical distribution industry in China 2.9 Increase in lifestyle related diseases 2.10 Biotechnology Market: The Strategic Industry for China 2.11 Focus on GMP leads to Quality and Compliance reforms 2.12 Government led initiatives to attract foreign players 2.13 Talent Pool Availability View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market 2.14 Increased Outsourcing of Drug Discovery boosting the Chinese CRO Market 2.15 Regulatory Environment 2.15.1 Drug filing 2.15.2 Advertisements 2.15.3 Drugs Pricing & Reimbursement 2.16 Traditional Chinese Medicine 3. China Pharmaceutical Market Forecast 3.1 Chinese Pharmaceutical Market; Pharmaceutical Sales (OTC and Prescription market) 3.1.1 Chinese pharmaceutical sales market Forecast 2008-2024 3.1.2 China Pharmaceutical Sales Market by Generic and Patented Drug Sales 3.1.3 Generic Drugs Market in China
3.2 The Chinese Patented Drugs Market 3.3 China Pharmaceutical Sales Market by Prescription and OTC Drug Sales 3.3.1 Prescription Drug Market in China 3.3.2 Over-the-Counter Drugs Market in China 4. The Chinese Medical Device Market 4.1 Overview of the Medical Device Market in China 4.2 China Medical Devices Market: Diagnostic Imaging Segment 4.3 China Medical Devices Market: Patient Aids Segment 4.4 China Medical Devices Market: Consumables Segment View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market 4.5 The China Medical Devices Market: Dental Segment 4.6 China Medical Devices Market: Orthopaedic Segment 4.7 Challenges & Opportunities in the Medical devices market 4.7.1 Opportunities 4.7.2 Challenges 4.8 China Medical Devices Market: Players Landscape 4.8.1 Multinational Corporations in the Chinese Medical devices market 4.8.1.1 General Electric Healthcare 4.8.1.1 Medtronic, Inc.
4.8.1.2 Zimmer - Zimmer Holdings, Inc. 4.8.1.3 Stryker Corporation 4.8.1.4 Siemens Healthcare 4.8.1.5 Johnson & Johnson 4.8.1.6 Philips Healthcare (Suzhou) Co., Ltd 4.9 Key Domestic companies in the Chinese Medical devices market 4.9.1 Weigao group View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market 4.9.2 Mindray Medical International Limited 4.9.3 MicroPort Scientific Corporation 4.9.4 Biosensors International Group, Ltd 5. The Chinese API Market 5.1 API Overview 5.1.1 Global API Market 5.1.1.1 APAC API Market 5.1.1.2 The Chinese API Market 5.2 Major Growth Drivers for the Chinese API Market 5.3 Key Challenges 5.4 China API Market: Players Landscape
5.4.1 Major Chinese API Manufacturers 5.4.1.1 Zhejiang Hisun Pharmaceutical Co. Ltd 5.4.1.2 Jiangsu Hengrui Medicine Co., Ltd 5.4.1.3 CSPC Pharmaceutical Group Limited 5.4.1.4 Shandong Xinhua Pharmaceutical Company Limited 5.4.1.5 Shanghai Pharma Holding Company Limited 5.4.1.6 North China Pharmaceutical Group Corp. View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market 6 Key Chinese Therapeutic Markets 6.1 Cardiovascular Diseases 6.1.1 Chinese Cardiovascular Disease treatments market forecast 2014-2024 6.2 Infectious Diseases 6.2.1 Chinese Infectious Disease treatments market forecast 2014-2024 6.3 Oncology 6.3.1 Chinese Oncology treatments market forecast 2014-2024 6.4 Nervous System 6.4.1 The Chinese Nervous System market forecast 2014-2024 6.5 Alimentary Tract & Metabolism 6.5.1 The Chinese Alimentary Tract & Metabolism treatments market forecast 2014-2024
7. Major Players 7.1 Pfizer 7.2. Bayer 7.3. Sanofi-Aventis 7.4. AstraZeneca 7.5. Roche 7.6. Merck and Co. 7.7. Novartis View Full Report with TOC @ http://www.radiantinsights.com/research/thechinese-pharmaceutical-market 7.8. GSK 7.9. Novo Nordisk (Novo Nordisk (China) Pharmaceutical Co., Ltd.) 8. Expert Opinion 8.1 Dr Cezary Statuch – Vice President Bristol-Myers Squibb, China 8.2 Dr Eugene Buff – Primary Care Innovation Consulting & UsTech Discovery LLC
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. For more information visit: Radiant Insights Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://sagarkadam.kinja.com/